



## Submission Guidelines

All submissions for oral or poster presentations must be submitted by **Thursday 8 August 2024 5pm AEST** (Australian Eastern Standard Time). To submit your abstract, please [click here](#) and follow the directions in the online abstract submission portal.

### Introduction

- All submissions must comply with these guidelines.
- The Scientific Committee reserves the right to reject or return for re-submission with a strict deadline any abstract that does not comply with these guidelines.

### Abstract Topic

- For each abstract, select ONE of the listed Topics and ONE Category of basic science, translational, or clinical research.
- Based on these selections the committee will assign reviewers with corresponding expertise to rate your abstract.

#### Step 1 – Topic – Select one only

- Functional Genomics
- Advanced Genome and Transcriptome Analytics
- Advanced Clinical Data Analytics
- Data Integration
- Drug screening and pre-clinical testing
- Advanced therapeutics, therapy, novel targets and agents, clinical trials
- Psychosocial
- Health Economics
- Health Systems Implementation

#### Step 2 – Category – Select one only

- Basic science
- Translational
- Clinical

### Abstract Content

Abstracts should comprise the following elements entered into the submission portal in the corresponding sections.

#### 1. Title

- A brief descriptive title (maximum of 12 words) in Sentence case. Trademarks are not permitted.



## 2. Authors and Affiliations

- Institutional affiliations should include the city, state, and country. Each affiliation should be input in a separate section and will be allocated a superscript number.
- Authors' names and details should be entered as instructed in the portal.
- You must also indicate who will be the presenting author.

## 3. Abstract

- There is a maximum of 300 words allowed only (do not include tables, charts, and pictures). The abstract text must not exceed 300 words, excluding the abstract title and author details.
- Text must be submitted as plain text without formatting. A limited number of symbols are available from the Special Character Keyboard.
- Tables, graphs, and charts are NOT permitted in abstracts.
- Abstracts should be carefully proofread and free of typographical and grammatical errors. The Scientific Committee reserves the right to correct abstracts for obvious spelling or grammatical errors without notice.
- Standard abbreviations may be used for common terms only. Otherwise, any abbreviation should be given in brackets after the first full use of the word.
- Abbreviations may be used in the title, provided the name in full is outlined in the body of the abstract.

## Abstract sections

Abstracts should contain the following sections, each beginning a new paragraph:

- Background:** Aims and objectives of the study, what the study covers, relevant background information, and an outline of how the information will be presented.
- Methods:** Outline how the study was carried out and how the information was obtained.
- Results:** Present the results obtained from data gathering and the study. Results should be presented clearly, and concisely and record only the facts.
- Conclusion:** State or summarise the main points or findings of the study. This is where the aims of the study are revisited. No new information should be presented in this section.

## Session Recording

Please note that by submitting your abstract and or agreeing to present, that you are consenting to your presentation being recorded for upload to [www.luminesceallianceconference.org.au](http://www.luminesceallianceconference.org.au) post the conference. If you do not wish your session to be recorded, you can tick the opt out option during the submission process.

## Terms and Conditions

- All abstracts must be original work and must be related to paediatric research and one of the major topics listed under "Abstract topic".
- Abstracts must be submitted by the first or corresponding author and only 2 abstracts per first



author can be submitted.

- An abstract must contain sufficient information so that, if published, it will be a complete report independent of presentation.
- The text should not contain statements alluding to results or conclusions not presented within the text.
- Abstracts pertaining to commercial promotion of a proprietary product will not be accepted.
- The Scientific Committee has the right of refusal to any abstract submitted at all times.
- All presenting authors (maximum of two) if selected by the Scientific Committee must register and pay to attend the Conference by **Friday 4 October 2024**. Alternate presenters need to be approved by the Scientific Committee.

### Abstract Review

All submitted abstracts will be reviewed by at least two reviewers. In evaluating each abstract, reviewers will be unaware of authors or institutions involved with the work described in the abstract. The following criteria will be used when assessing the abstract:

- Does the abstract address a relevant area related to paediatric research and the major topics listed? Is the methodology adequate and acceptable? Have the data/findings been interpreted appropriately? Are the results clearly presented? Are the conclusions supported by the presented data? Are the contents of the abstract clear and intelligible?

Abstracts on completed studies and research outcomes may be given preference in selecting the oral presentations, over abstracts that do not report results but indicate that they will be reported at the meeting or contain descriptions of trial methodology.

### Notification of Outcome

Notification of outcome/acceptance will be emailed to the submitting author by **Friday 13 September 2024**.

It is the submitting author's responsibility to notify all other authors about the outcome of the reviewers' decision.

### Oral Presentation and Poster Display

From the accepted abstracts a selection will be scheduled for the concurrent oral presentation session and the rapid-fire oral presentation and poster display only.

For all accepted abstracts, further details regarding the oral presentation (PowerPoint presentation) and poster presentation (poster size, format, style and layout etc.) will be communicated to the submitting author.

### Presenting Author Registration

If the presenting author cannot present at the time/date for the scheduled concurrent oral presentation session and the rapid-fire oral presentation an alternate can be considered. Alternate presenters need to



be approved by the Scientific Committee.

### No-Show Policy

Should a presenting author be absent without notice during the oral presentation sessions where the abstract is scheduled to be presented, the presentation will be cancelled.

### Trademarks

Trademarks may be used in the abstract text but only in brackets and only once, i.e. the first time the product/service is mentioned. The identity of drugs/technologies described in the abstract should be disclosed using a generic name, a brief description or a reference to a public source.

### Abstract Publication / Copyright

Submission of an abstract grants Luminesce Alliance permission to publish the abstract in the Luminesce Alliance 2024 Conference Online Program as well as the Luminesce Alliance websites [www.luminesceallianceconference.org.au](http://www.luminesceallianceconference.org.au) and [www.luminesce.org.au](http://www.luminesce.org.au). Links to the online program will be made from the Luminesce Alliance monthly newsletter, social media posts and industry publications (such as OHMR and Research Australia).

It is expected that the primary author/presenter will consult with co-authors/supervisors to provide consent for the abstract to be published. Abstract authors retain full copyright.

### Contact

For questions or assistance which abstract submission please contact [lac2024@expertevents.com.au](mailto:lac2024@expertevents.com.au).